New data identify age, anti-β2GP1 antibodies, and low C3 as key risk factors for cerebral small vessel disease in systemic ...
Phase 3 trial data show subcutaneous anifrolumab improves BICLA response rates and reduces oral corticosteroid use in ...
Verywell Health on MSN
Types of complement 3 glomerulopathy: How they differ and what that means
Medically reviewed by Erika Prouty, PharmD Key Takeaways There are two types of complement 3 glomerulopathy: dense deposit ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A commercially ...
A new study highlights potential therapies to decrease cardiovascular risk in people with systemic lupus erythematosus (SLE) and identifies biomarkers that may indicate a heightened risk.
Over 20 years, 8.4% of patients with lupus developed end-stage kidney disease, a study found. Investigators have identified risk factors for development of end-stage kidney disease (ESKD) after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback